1. Home
  2. CLLS vs DSX Comparison

CLLS vs DSX Comparison

Compare CLLS & DSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • DSX
  • Stock Information
  • Founded
  • CLLS 1999
  • DSX 1999
  • Country
  • CLLS France
  • DSX Greece
  • Employees
  • CLLS N/A
  • DSX N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • DSX Marine Transportation
  • Sector
  • CLLS Health Care
  • DSX Consumer Discretionary
  • Exchange
  • CLLS Nasdaq
  • DSX Nasdaq
  • Market Cap
  • CLLS 144.4M
  • DSX 172.5M
  • IPO Year
  • CLLS 2007
  • DSX 2005
  • Fundamental
  • Price
  • CLLS $1.58
  • DSX $1.39
  • Analyst Decision
  • CLLS Buy
  • DSX Hold
  • Analyst Count
  • CLLS 3
  • DSX 1
  • Target Price
  • CLLS $7.00
  • DSX $3.00
  • AVG Volume (30 Days)
  • CLLS 79.4K
  • DSX 180.6K
  • Earning Date
  • CLLS 05-27-2025
  • DSX 05-27-2025
  • Dividend Yield
  • CLLS N/A
  • DSX 2.87%
  • EPS Growth
  • CLLS N/A
  • DSX N/A
  • EPS
  • CLLS N/A
  • DSX 0.05
  • Revenue
  • CLLS $49,217,000.00
  • DSX $228,209,000.00
  • Revenue This Year
  • CLLS $48.52
  • DSX N/A
  • Revenue Next Year
  • CLLS $5.17
  • DSX $12.03
  • P/E Ratio
  • CLLS N/A
  • DSX $26.36
  • Revenue Growth
  • CLLS 435.38
  • DSX N/A
  • 52 Week Low
  • CLLS $1.10
  • DSX $1.27
  • 52 Week High
  • CLLS $3.32
  • DSX $3.22
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 60.44
  • DSX 35.69
  • Support Level
  • CLLS $1.46
  • DSX $1.38
  • Resistance Level
  • CLLS $1.65
  • DSX $1.52
  • Average True Range (ATR)
  • CLLS 0.08
  • DSX 0.04
  • MACD
  • CLLS -0.00
  • DSX 0.00
  • Stochastic Oscillator
  • CLLS 75.00
  • DSX 3.57

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About DSX Diana Shipping inc. common stock

Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.

Share on Social Networks: